News – Page 1044 – Endpoints News

Director of diversity and inclusion arrives at MassBio; Jerome Jabbour takes the helm at Matinas; Ex-Eli Lilly CFO ...

8 years ago

Congress approves government spending bill with increased FDA funding

8 years ago

GSK drops out of $20B race for Pfizer's consumer health unit — shares surge

8 years ago

In a blow to its biggest revenue driver, Indivior loses patent battle with generics maker Alvogen

8 years ago

MorphoSys files for $150M IPO to fuel its hopeful DLBCL drug launch

8 years ago

Poised for an FDA pitch, Novartis lays out all its PhIII cards on MS drug siponimod

8 years ago

Another immunometabolism deal? Johns Hopkins spinout Dracen lands $36M investment from Deerfield

8 years ago

Unicorn Moderna joins lineup to list on Hong Kong's exchange; Processa licenses compound from Concert

8 years ago

Novo Nordisk's pick for new chairman signals its ongoing pursuit of M&A deals

8 years ago

AbbVie shares tank on Rova-T flop, sudden retreat from accelerated approval pitch

8 years ago

Sun Pharma screeches to the psoriasis finish line with FDA OK of Ilumya. Too bad rivals J&J and others beat them to ...

8 years ago

Third Rock debuts immunometabolism startup Rheos with $60M launch round

8 years ago

House Republicans mount a successful comeback campaign for right-to-try bill

8 years ago

Cashing in on PhII trial success, Arena to raise $353M to fuel PhIII etrasimod/ralinepag trials

8 years ago

12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you

8 years ago

The PCSK9 of NASH? Regeneron and Alnylam join forces to tackle a promising target for severe liver diseases

8 years ago

Proteostasis pulls stock offering following Kerrisdale short report; Cidara issues supplemental PhII rezafungin data

8 years ago

Shakeup at China FDA after chief vaults to the helm of a regulatory umbrella group, new agency head named

8 years ago

Despite some nagging demerits, Incyte CEO Hervé Hoppenot still bagged $16M in compensation — a 35% increase

8 years ago

NYC's biotech scene gets cash and office space with Beacon's new incubator

8 years ago

Another mega-startup: China investors back TCR2's $125M cash round to fuel a preclinical assault on solid tumors

8 years ago

Falling behind giant migraine drug rivals, Alder ousts founder Randy Schatzman — could a buyout be next?

8 years ago

GSK’s Luke Miels applies budget shock therapy to shake up the pharma group, refocus on blockbusters

8 years ago

Celgene goes all-out on neurodegeneration and Alzheimer’s, triggering blockbuster deal with $150M in cash for ...

8 years ago

First page Previous page 1041 1042 104310441045 1046 1047 Next page Last page